Have a feature idea you'd love to see implemented?
Let us know!
REGN Regeneron Pharmaceuticals Inc
Price (delayed)
$928.9
Market cap
$102.4B
P/E Ratio
23.04
Dividend/share
N/A
EPS
$40.32
Enterprise value
$103.18B
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it
Highlights
The equity has grown by 17% year-on-year and by 4.5% since the previous quarter
The company's EPS rose by 12% QoQ
REGN's price to earnings (P/E) is 33% higher than its 5-year quarterly average of 17.3 but 6% lower than its last 4 quarters average of 24.6
The quick ratio has contracted by 2.2% YoY
Key stats
What are the main financial stats of REGN
Market
Valuations
Earnings
Shares outstanding
110.23M
Market cap
$102.4B
Enterprise value
$103.18B
Price to earnings (P/E)
23.04
Price to book (P/B)
3.63
Price to sales (P/S)
7.44
EV/EBIT
22.17
EV/EBITDA
20.2
EV/Sales
7.65
Revenue
$13.49B
EBIT
$4.65B
EBITDA
$5.11B
Free cash flow
$3.35B
Per share
Balance sheet
Liquidity
EPS
$40.32
Free cash flow per share
$30.98
Book value per share
$255.98
Revenue per share
$124.78
TBVPS
$323.63
Total assets
$36.09B
Total liabilities
$7.88B
Debt
$2.7B
Equity
$28.21B
Working capital
$15.57B
Debt to equity
0.1
Current ratio
5.44
Quick ratio
4.43
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
37.9%
Gross margin
86.2%
Net margin
32%
Operating margin
28.9%
Return on assets
12.7%
Return on equity
16.3%
Return on invested capital
15.7%
Return on capital employed
14.3%
Return on sales
34.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
REGN stock price
How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
-1.33%
1 week
-6.95%
1 month
-11.19%
1 year
15.49%
YTD
5.76%
QTD
-11.64%
Financial performance
How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$13.49B
Gross profit
$11.62B
Operating income
$3.9B
Net income
$4.32B
Gross margin
86.2%
Net margin
32%
Regeneron Pharmaceuticals's operating margin has decreased by 15% YoY
Regeneron Pharmaceuticals's net income has increased by 12% QoQ
The operating income fell by 10% YoY
The net margin has increased by 9% from the previous quarter but it has decreased by 6% YoY
Growth
What is Regeneron Pharmaceuticals's growth rate over time
Valuation
What is Regeneron Pharmaceuticals stock price valuation
P/E
23.04
P/B
3.63
P/S
7.44
EV/EBIT
22.17
EV/EBITDA
20.2
EV/Sales
7.65
REGN's price to earnings (P/E) is 33% higher than its 5-year quarterly average of 17.3 but 6% lower than its last 4 quarters average of 24.6
The company's EPS rose by 12% QoQ
The equity has grown by 17% year-on-year and by 4.5% since the previous quarter
REGN's price to book (P/B) is 11% less than its 5-year quarterly average of 4.1 and 4.5% less than its last 4 quarters average of 3.8
The P/S is 18% higher than the 5-year quarterly average of 6.3
The revenue has increased by 6% YoY and by 3% QoQ
Efficiency
How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on invested capital has decreased by 19% YoY but it has increased by 9% QoQ
Regeneron Pharmaceuticals's return on equity has decreased by 13% YoY but it has increased by 8% QoQ
The return on assets has declined by 13% year-on-year but it has increased by 8% since the previous quarter
The company's return on sales rose by 10% QoQ but it fell by 10% YoY
Dividends
What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for REGN.
Financial health
How did Regeneron Pharmaceuticals financials performed over time
Regeneron Pharmaceuticals's total liabilities has increased by 19% YoY and by 7% QoQ
REGN's total assets is up by 18% year-on-year and by 5% since the previous quarter
The debt is 90% less than the equity
The equity has grown by 17% year-on-year and by 4.5% since the previous quarter
REGN's debt to equity is down by 9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.